SuperGen receives Nipent patent

By Elaine Rigoli

Tampa, Fla., June 2 - SuperGen, Inc. announced the issuance of U.S. Patent No. 7,037,900 B2 entitled, "Composition and Method for Treating Graft-versus-Host Disease."

SuperGen said the patent contains 39 claims relating to the composition and methods for treating graft-versus-host disease and, more specifically, to the administration of inhibitors of adenosine deaminase (ADA).

In particular, novel formulations of ADA inhibitors such as pentostatin are used for suppressing T-lymphocyte mediated immune responses while minimizing systemic toxicity of the drug.

"This is SuperGen's first patent relating to the use of Nipent in graft-versus-host disease, and it enhances the potential value of our franchise beyond the current approved indication of hairy cell leukemia," chief operating officer Edward L. Jacobs said in a news release.

SuperGen is a pharmaceutical company based in Dublin, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.